Late Stage Chronic Kidney Disease Drugs Global Market Report 2025

Description

Late-stage chronic kidney disease drugs are medications designed to treat end-stage chronic kidney disease, aiming to improve patients' quality of life by arresting the progression of the disease and, in some cases, preventing or delaying the need for dialysis or a kidney transplant.

The primary product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics, for instance, constitute a class of medications that enhance signaling and reduce parathyroid hormone (PTH) levels by activating the calcium-sensing receptor allosterically. These drugs address various indications related to late-stage chronic kidney disease, such as hyperparathyroidism, hyperphosphatemia, and hyperkalemia. The distribution channels for these drugs typically include hospital pharmacies, online pharmacies, and retail pharmacies.

The late stage chronic kidney disease drugs market research report is one of a series of new reports from The Business Research Company that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.08 billion in 2024 to $7.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $12.2 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for CKD management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.

The high prevalence of chronic kidney diseases is expected to drive the growth of the late-stage chronic kidney disease drug market in the future. Chronic kidney diseases encompass a wide range of conditions that impact the structure and function of the kidneys. Drugs for late-stage chronic kidney disease are utilized to manage blood pressure in patients and reduce protein loss, helping to slow the progression of kidney impairment, alleviate symptoms, and prevent complications. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, estimated that approximately 14% of U.S. adults-around 35.5 million people-are living with chronic kidney diseases. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.

The increasing prevalence of diabetes is anticipated to drive the growth of the late-stage chronic kidney disease (CKD) drug market in the future. Diabetes is a chronic condition marked by elevated blood glucose levels, which can cause significant damage to the heart, blood vessels, eyes, kidneys, and nerves. It is a well-recognized risk factor for developing chronic kidney disease. Individuals with diabetes, particularly those with poorly managed blood sugar levels, face a heightened risk of progressing to late-stage CKD. As the global prevalence of diabetes rises, the incidence of CKD, especially in its advanced stages, is expected to rise correspondingly. For example, in March 2024, the Office for Health Improvement & Disparities, a UK government department, reported that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of patients achieving target HbA1c levels rose to 37.9%, marking the highest level recorded by the National Diabetes Audit (NDA). Therefore, the high prevalence of diabetes is propelling the growth of the late-stage chronic kidney disease drug market.

Product innovation emerges as a prominent trend gaining traction in the late-stage chronic kidney disease drug market, with major companies actively developing new drugs to maintain their market positions. For example, in February 2022, Bayer, a leading Germany-based pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. Finerenone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for patients with type two diabetes and chronic renal disease. The drug works by preventing the overactivation of the mineralocorticoid receptor (MR), believed to be a factor in the development of chronic kidney disease (CKD) and cardiovascular harm.

Key players in the late-stage chronic kidney disease drugs market are advancing technologies such as continuous subcutaneous infusion methods to enhance treatment effectiveness, improve patient outcomes, and streamline the drug development process. Continuous subcutaneous infusion technology provides a steady delivery of medication through a small device implanted under the skin, ensuring consistent therapeutic levels and increasing patient adherence. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA (for levodopa/foscarbidopa). This product facilitates a continuous infusion of levodopa, which is essential for maintaining stable dopamine levels in the bloodstream. This is vital for effectively managing symptoms, as it prolongs the duration of "on" time-periods when symptoms are well-managed-while reducing "off" time when symptoms reappear.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. This strategic acquisition strengthens AstraZeneca's cardiorenal pipeline by adding CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed to treat chronic kidney disorders. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, is the developer of baxdrostat. The acquisition enhances AstraZeneca's position in the late-stage chronic kidney disease drug market.

Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc

North America was the largest region in the late stage chronic kidney disease drugs market in 2024. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on late stage chronic kidney disease drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for late stage chronic kidney disease drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The late stage chronic kidney disease drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism; Late Stage Chronic Kidney Disease Induced Hyperphosphatemia; Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet; Etelcalcetide
2) By Vitamin D: Calcitriol; Doxercalciferol; Paricalcitol
3) By Sterols: Ergocalciferol; Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate; Patiromer; Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate; Calcium Carbonate
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25062

1. Executive Summary

2. Late Stage Chronic Kidney Disease Drugs Market Characteristics

3. Late Stage Chronic Kidney Disease Drugs Market Trends And Strategies

4. Late Stage Chronic Kidney Disease Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Late Stage Chronic Kidney Disease Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Late Stage Chronic Kidney Disease Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Late Stage Chronic Kidney Disease Drugs Market Growth Rate Analysis
5.4. Global Late Stage Chronic Kidney Disease Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Late Stage Chronic Kidney Disease Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Late Stage Chronic Kidney Disease Drugs Total Addressable Market (TAM)

6. Late Stage Chronic Kidney Disease Drugs Market Segmentation

6.1. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
6.2. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
Late Stage Chronic Kidney Disease Induced Hyperkalemia
6.3. Global Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
6.4. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cinacalcet
Etelcalcetide
6.5. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Vitamin D, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcitriol
Doxercalciferol
Paricalcitol
6.6. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Sterols, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ergocalciferol
Cholecalciferol
6.7. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Potassium Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sodium Polystyrene Sulfonate
Patiromer
Sodium Zirconium Cyclosilicate
6.8. Global Late Stage Chronic Kidney Disease Drugs Market, Sub-Segmentation Of Calcium-Based Phosphate Binders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcium Acetate
Calcium Carbonate

7. Late Stage Chronic Kidney Disease Drugs Market Regional And Country Analysis

7.1. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Late Stage Chronic Kidney Disease Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market

8.1. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Late Stage Chronic Kidney Disease Drugs Market

9.1. China Late Stage Chronic Kidney Disease Drugs Market Overview
9.2. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Late Stage Chronic Kidney Disease Drugs Market

10.1. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Late Stage Chronic Kidney Disease Drugs Market

11.1. Japan Late Stage Chronic Kidney Disease Drugs Market Overview
11.2. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Late Stage Chronic Kidney Disease Drugs Market

12.1. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Late Stage Chronic Kidney Disease Drugs Market

13.1. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Late Stage Chronic Kidney Disease Drugs Market

14.1. South Korea Late Stage Chronic Kidney Disease Drugs Market Overview
14.2. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Late Stage Chronic Kidney Disease Drugs Market

15.1. Western Europe Late Stage Chronic Kidney Disease Drugs Market Overview
15.2. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Late Stage Chronic Kidney Disease Drugs Market

16.1. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Late Stage Chronic Kidney Disease Drugs Market

17.1. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Late Stage Chronic Kidney Disease Drugs Market

18.1. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Late Stage Chronic Kidney Disease Drugs Market

19.1. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Late Stage Chronic Kidney Disease Drugs Market

20.1. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market

21.1. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market Overview
21.2. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Late Stage Chronic Kidney Disease Drugs Market

22.1. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Late Stage Chronic Kidney Disease Drugs Market

23.1. North America Late Stage Chronic Kidney Disease Drugs Market Overview
23.2. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Late Stage Chronic Kidney Disease Drugs Market

24.1. USA Late Stage Chronic Kidney Disease Drugs Market Overview
24.2. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Late Stage Chronic Kidney Disease Drugs Market

25.1. Canada Late Stage Chronic Kidney Disease Drugs Market Overview
25.2. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Late Stage Chronic Kidney Disease Drugs Market

26.1. South America Late Stage Chronic Kidney Disease Drugs Market Overview
26.2. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Late Stage Chronic Kidney Disease Drugs Market

27.1. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Late Stage Chronic Kidney Disease Drugs Market

28.1. Middle East Late Stage Chronic Kidney Disease Drugs Market Overview
28.2. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Late Stage Chronic Kidney Disease Drugs Market

29.1. Africa Late Stage Chronic Kidney Disease Drugs Market Overview
29.2. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Late Stage Chronic Kidney Disease Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape And Company Profiles

30.1. Late Stage Chronic Kidney Disease Drugs Market Competitive Landscape
30.2. Late Stage Chronic Kidney Disease Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Late Stage Chronic Kidney Disease Drugs Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Eli Lilly and Company
31.5. C.H. Boehringer Sohn AG & Co. KG
31.6. Amgen Inc.
31.7. Novo Nordisk A/S
31.8. Teva Pharmaceutical Industries Ltd.
31.9. Otsuka Pharmaceutical Co. Ltd.
31.10. Takeda Pharmaceutical Company Limited
31.11. Kyowa Kirin Co Ltd.
31.12. OPKO Health Inc.
31.13. Evotec SE
31.14. Ionis Pharmaceuticals Inc.
31.15. Akebia Therapeutics Inc.

32. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market

34. Recent Developments In The Late Stage Chronic Kidney Disease Drugs Market

35. Late Stage Chronic Kidney Disease Drugs Market High Potential Countries, Segments and Strategies

35.1 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Late Stage Chronic Kidney Disease Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer